**Supplementary Table 1**. Baseline characteristics according to different stages of AKI by the KDIGO in patients with COVID-19.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Characteristic**† | | **AKI (N=194)** | **Stage 1 (N=120)** | **Stage 2 (N=35)** | **Stage 3 (N=39)** | **P**\* |
| **Demographics** | |  |  |  |  |  |
| Age | | 60.6±17.4 | 57.5±18.5 | 66.8±15.5 | 6.7±13.7 | **0.005** |
| Sex | Female | 29(14.9%) | 14(11.7%) | 5(14.3%) | 10(25.6%) | 0.104 |
| Male | 165(85.1%) | 106(88.3%) | 30(85.7%) | 29(74.4%) |
| **Comorbidities** | |  |  |  |  |  |
| Hypertension | | 104(53.6%) | 57(47.5%) | 22(62.9%) | 25(64.1%) | 0.094 |
| Diabetes mellitus | | 82(42.3%) | 42(35.0%) | 23(65.7%)\*\* | 17(43.6%) | **0.005** |
| Cardiac disease | | 57(29.4%) | 37(30.8%) | 7(20.0%) | 13(33.3%) | 0.387 |
| Cerebrovascular disease | | 12(6.2%) | 8(6.7%) | 3(8.6%) | 1(2.6%) | 0.529 |
| Chronic lung disease | | 16(8.2%) | 12(10.0%) | 1(2.9%) | 3(7.7%) | 0.397 |
| Chronic kidney disease | | 17(8.8%) | 6(5.0%) | 8(22.9%)\*\* | 3(7.7%) | **0.004** |
| Malignancy | | 11(5.7%) | 4(3.3%) | 6(17.1%)\*\* | 1(2.6%) | **0.018** |
| **Drug history** | |  |  |  |  |  |
| ACEI/ARB | | 55(28.4%) | 26(21.7%) | 10(28.6%) | 19 (48.7%)\*\* | **0.003** |

† Data are presented as mean±standard deviation number (%).

**\*** Statistically significant P-values are bolded.

\*\* Statistically significant Bonferroni adjusted P-values (P<0.0083).

ACEI: angiotensin converting enzyme inhibitors; ARB: angiotensin II receptor blockers; AKI: acute kidney injury.

**Supplementary Table 2.** Logistic regression analysis for risk indicators of AKI development during hospitalization in patients with positive PCR test for COVID-19.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Model 1**† | | | **Model 2**‡ | | |
|  | Odds ratio | 95%CI | **P\*** | Odds ratio | 95%CI | **P\*** |
| Age | 1.03 | 1.01-1.06 | **0.014** |  |  |  |
| Male sex | 3.88 | 1.83-8.20 | **<0.001** | 5.99 | 2.11-17.01 | **0.001** |
| Severity | 1.89 | 0.76-4.74 | **0.172** |  |  |  |
| Hypertension | 3.39 | 1.64-7.00 | **0.001** |  |  |  |
| Diabetes mellitus | 3.72 | 1.79-7.73 | **<0.001** | 3.15 | 1.18-8.41 | **0.022** |
| Cardiac disease | 4.40 | 1.82-10.63 | **0.001** |  |  |  |
| Chronic kidney disease | 8.88 | 1.04-76.02 | **0.046** | 10.79 | 0.87-133.05 | 0.064 |
| NLR | 1.17 | 1.05-1.30 | **0.004** |  |  |  |
| Urea (mg/dL) | 1.05 | 1.03-1.07 | **<0.001** | 1.03 | 1.01-1.06 | **0.002** |
| CRP (mg/L) | 1.01 | 1.00-1.01 | **0.013** |  |  |  |

**\*** Statistically significant P-values are bolded.

† Univariate binary logistic regression.

‡ Multivariate binary logistic regression adjusted for age, sex, severity, hypertension, diabetes mellitus, cardiac disease, NLR, urea, and CRP.

AKI: acute kidney injury; CRP: C-reactive protein; NLR: neutrophil-to-lymphocyte ratio; PCR: polymerase-chain-reaction.